"Acer Medical" VeriSee GLC
Winning Reason
Glaucoma is the second leading cause of vision loss worldwide and is characterized by its irreversible nature. Our AI-assisted glaucoma screening software leverages a decade of clinical data from National Taiwan University Hospital, validated by a consensus of three expert ophthalmologists. By utilizing AI to analyze critical pathological markers in color fundus images, the system achieves a diagnostic accuracy of 85%, significantly accelerating the diagnostic process and enabling large-scale population screening. The solution has secured medical device certifications in Taiwan (TFDA), Thailand, Malaysia, and Indonesia, demonstrating robust export potential for global healthcare markets.
Product Feature
VeriSee GLC is a state-of-the-art AI software that assists clinicians in identifying glaucoma suspects using standard color fundus images.
Key Features:
1. Triple-Indicator Evaluation: Analyzes vertical cup-to-disc ratio (VCDR), superior/inferior rim-to-disc ratio (RDR), and retinal nerve fiber layer (RNFL) defects to ensure alignment with ophthalmological standards.
2. Proven Performance: Validated by clinical trials with 90.3% sensitivity, 82.1% specificity, and 85.0% accuracy.
3. AI Explainability: Outlines optic cup/disc contours and provides numerical values, offering transparent evidence for clinical decisions.
4. Efficient Workflow: Integrates with fundus cameras for rapid analysis and timely referrals in checkup centers and clinics.